Conaway C C, Jiao D, Kelloff G J, Steele V E, Rivenson A, Chung F L
Division of Carcinogenesis and Molecular Epidemiology, American Health Foundation, Valhalla, NY 10595, USA.
Cancer Lett. 1998 Feb 13;124(1):85-93. doi: 10.1016/s0304-3835(97)00454-0.
Four agents, fumaric acid (FA), N-acetylcysteine (NAC), N-(4-hydroxyphenyl) retinamide (4-HPR) and beta-carotene (beta-CT), were evaluated for potential chemopreventive activity using the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung tumor model in female A/J mice. The agents were evaluated in both 16-week and 52-week bioassays at two dose levels corresponding to 0.8 maximum tolerated dose (MTD) and 0.4 MTD administered throughout the bioassay either in the diet (FA, 160 and 80 mmol/kg diet; NAC, 160 and 80 mmol/kg diet; 4-HPR, 4 and 2 mmol/kg diet) or by subcutaneous injection twice a week (beta-CT, 32 and 16 mg/kg b.w.). Mice were treated with a single i.p. dose of 10 micromol NNK in saline 1 week after administration of test agent. Lung adenomas were evaluated in the 16-week bioassay, whereas both adenomas and adenocarcinomas of the lung were determined in the 52-week bioassay. Both bioassays showed that all four agents did not significantly inhibit the total tumor incidence and multiplicity of the lung. However, the incidence of adenocarcinomas was reduced (P < 0.01) at 52 weeks in NNK groups given either 0.8 MTD NAC or 0.8 MTD beta-CT compared with the NNK control group. The decreases in adenocarcinomas were accompanied by corresponding increases in adenomas in these treatment groups. Thus, this study showed that FA, NAC, 4-HPR and beta-CT did not inhibit the total tumor formation, however, at the higher doses both NAC and beta-CT significantly retarded the malignant progression in the lung of NNK-treated A/J mice.
使用烟草特异性致癌物4-(甲基亚硝胺基)-1-(3-吡啶基)-1-丁酮(NNK)诱导雌性A/J小鼠肺癌模型,对富马酸(FA)、N-乙酰半胱氨酸(NAC)、N-(4-羟基苯基)视黄酰胺(4-HPR)和β-胡萝卜素(β-CT)这四种试剂的潜在化学预防活性进行了评估。在16周和52周的生物测定中,以两种剂量水平对这些试剂进行评估,这两种剂量水平分别对应于整个生物测定期间在饮食中给予的0.8最大耐受剂量(MTD)和0.4 MTD(FA,160和80 mmol/kg饮食;NAC,160和80 mmol/kg饮食;4-HPR,4和2 mmol/kg饮食),或通过每周皮下注射两次(β-CT,32和16 mg/kg体重)。在给予测试试剂1周后,用10微摩尔NNK的单一腹腔注射剂量处理小鼠。在16周的生物测定中评估肺腺瘤,而在52周的生物测定中测定肺腺瘤和腺癌。两种生物测定均显示,所有四种试剂均未显著抑制肺肿瘤的总发生率和多发性。然而,与NNK对照组相比,给予0.8 MTD NAC或0.8 MTDβ-CT的NNK组在52周时腺癌的发生率降低(P<0.01)。在这些治疗组中,腺癌的减少伴随着腺瘤的相应增加。因此,本研究表明,FA、NAC、4-HPR和β-CT均未抑制肿瘤的总体形成,然而,在较高剂量下,NAC和β-CT均显著延缓了NNK处理的A/J小鼠肺部的恶性进展。